A challenge for TRAIL-based therapies is the ability to distribute and deliver TRAIL to the tumor, and combinations with nanoparticles (NPs) have also been developed to help enable this (Sadeghnezhad et al., 2019). This evidence concerns the gene TNFSF10 and neoplasm.